



AmeriHealth Caritas
District of Columbia

To: AmeriHealth Caritas District of Columbia Providers
Date: February 23, 2022
Subject: **Formulary Update: Aimovig® Product Removal**

Summary: Effective March 30, 2022, the Aimovig® products below will be removed from the AmeriHealth Caritas District of Columbia drug formulary.

Enrollees currently receiving any of the products listed below on the left will require a new prescription for an alternative product. Enrollees for whom it is not medically advisable to change therapy will require prior authorization to continue to receive coverage for the non-formulary products.

Formulary Removals	
Product List	Alternative Product(s)
<ul style="list-style-type: none">• Aimovig® (ereenumab-aooe) 70MG/ML subcutaneous auto-injectors• Aimovig® (ereenumab-aooe) 140MG/ML subcutaneous auto-injector	<ul style="list-style-type: none">• Emgality® (galcanezumab-gnlm) 120MG/ML subcutaneous pen injector• Emgality® (galcanezumab-gnlm) 100MG/ML subcutaneous prefilled syringes• Emgality® (galcanezumab-gnlm) 120MG/ML subcutaneous prefilled syringe

If you have questions about this communication, please contact the AmeriHealth Caritas District of Columbia Provider Pharmacy Services at 1-888-602-3741.